An analysis identified the top 20 blockbuster drugs facing key U.S. patent expirations between 2026 and 2029, representing roughly $176.4 billion in annual sales. The report links looming exclusivity losses to the recent surge in M&A and strategic deals as big pharma races to refill revenue gaps before generics and biosimilars arrive. GEN’s breakdown highlights major names and years of expiration and cites recent industry transactions—Johnson & Johnson’s Intra‑Cellular Therapies buy and Merck’s acquisition of Verona Pharma—as examples of how companies are reshaping pipelines to mitigate the cliff. The finding underscores a concentrated revenue exposure that is driving dealmaking, pipeline prioritization and lifecycle management strategies across biopharma.